Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 8/20 | 0.62 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563150 | 0.95 | SLC16A3 (0.68) | SLC16A3SLC40A1RAD52MRGPRX4MRGPRX1 | |
| SCHEMBL3559725 | 0.89 | SLC16A3 (0.58) | SLC16A3SLC40A1RAD52MRGPRX1SLC22A12 | |
| SCHEMBL3551918 | 0.86 | MEN1 (0.50) | SLC16A3SLC40A1RAD52MRGPRX1SLC22A12 | |
| SCHEMBL3557901 | 0.85 | SLC16A3 (0.64) | SLC16A3SLC40A1MRGPRX4SLC22A12 | |
| SCHEMBL3558721 | 0.84 | SLC16A3 (0.51) | SLC16A3SLC22A12ALPLPTK2BIDH1 | |
| SCHEMBL3560779 | 0.84 | SLC16A3 (0.64) | SLC16A3SLC40A1RAD52MRGPRX1ALPL | |
| SCHEMBL3561067 | 0.84 | SLC16A3 (0.67) | SLC16A3MRGPRX4PTK2BSMN1; SMN2RAB9A | |
| SCHEMBL3555480 | 0.84 | SLC16A3 (0.59) | SLC16A3MRGPRX4PTK2BSMN1; SMN2RAB9A | |
| SCHEMBL3554994 | 0.83 | SLC16A3 (0.50) | SLC16A3MRGPRX4SLC22A12ALPLPTK2B | |
| SCHEMBL3557128 | 0.83 | MEN1 (0.49) | SLC16A3SLC40A1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885SLC40A1 1414/4885RAD52 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.